Susan Serrao

KYW Newsradio delves into why the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of the NIAID Strategic Plan for COVID-19 Research and what they hope to find. Dr. John Gallin, Chief Scientific Officer of the NIH Clinical Center and the NIH Associate Director for Clinical Research and Dr. Susan Levinson, […]

MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of the NIAID Strategic Plan for COVID-19 Research. BioAegis’ lead product, recombinant human plasma gelsolin (rhu-pGSN), is based on this highly abundant circulating human protein. This study is a critical

BioAegis says its ‘inflammation regulator’ is best weapon to fight COVID-19 Monday, May 11, 2020 | By Barbara Booth KEY POINTS: BioAegis Therapeutics believes that its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), is a viable therapeutic option for patients suffering from severe lung injury due to Covid-19. The private clinical stage company is

MORRISTOWN, N.J., April 27, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. has highlighted recently published gene expression data in animal studies where recombinant human plasma gelsolin (rhu-pGSN) significantly increased survival in pneumonia due to severe influenza.  Importantly, the gene expression analysis of lung tissue showed that gelsolin treatment downregulated genes associated with the over-exuberant production

MORRISTOWN, N.J., April 02, 2020 (GLOBE NEWSWIRE) — BioAegis Therapeutics Inc. is a clinical stage, private company focused on developing therapies for infectious, inflammatory, and degenerative diseases. Building upon intellectual property licensed from Harvard Medical School, BioAegis believes that its lead product, recombinant human plasma gelsolin therapy (rhu-pGSN), should be considered as a viable therapeutic

Our Chief Medical Officer and infectious disease expert, Dr. Mark DiNubile, was recently interviewed for a KYW InDepth podcast. Highlights of the podcast include:  What happens to our lungs when COVID-19 attacks our bodies and why some people end up in the ICU on ventilators. How the naturally-occurring human protein, plasma gelsolin, works in our